Cargando…
Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
Migraine is a potentially disabling disorder, yet it remains underdiagnosed and undertreated. The release of the neuropeptide calcitonin gene-related peptide (CGRP) in the trigemino-cerebrovascular system plays a vital role in the evolution of migraine. It enhances peripheral sensitization by mediat...
Autores principales: | Aditya, Suruchi, Rattan, Aditya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997852/ https://www.ncbi.nlm.nih.gov/pubmed/36909005 http://dx.doi.org/10.4103/sjmms.sjmms_95_22 |
Ejemplares similares
-
Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021) -
Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017) -
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022) -
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023) -
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)